Glucagon-like peptide-2 protects against TPN-induced intestinal hexose malabsorption in enterally refed piglets.
Premature infants receiving chronic total parenteral nutrition (TPN) due to feeding intolerance develop intestinal atrophy and reduced nutrient absorption. Although providing the intestinal trophic hormone glucagon-like peptide-2 (GLP-2) during chronic TPN improves intestinal growth and morphology, it is uncertain whether GLP-2 enhances absorptive function. We placed catheters in the carotid artery, jugular and portal veins, duodenum, and a portal vein flow probe in piglets before providing either enteral formula (ENT), TPN or a coinfusion of TPN plus GLP-2 for 6 days. On postoperative day 7, all piglets were fed enterally and digestive functions were evaluated in vivo using dual infusion of enteral ((13)C) and intravenous ((2)H) glucose, in vitro by measuring mucosal lactase activity and rates of apical glucose transport, and by assessing the abundances of sodium glucose transporter-1 (SGLT-1) and glucose transporter-2 (GLUT2). Both ENT and GLP-2 pigs had larger intestine weights, longer villi, and higher lactose digestive capacity and in vivo net glucose and galactose absorption compared with TPN alone. These endpoints were similar in ENT and GLP-2 pigs except for a lower intestinal weight and net glucose absorption in GLP-2 compared with ENT pigs. The enhanced hexose absorption in GLP-2 compared with TPN pigs corresponded with higher lactose digestive and apical glucose transport capacities, increased abundance of SGLT-1, but not GLUT-2, and lower intestinal metabolism of [(13)C]glucose to [(13)C]lactate. Our findings indicate that GLP-2 treatment during chronic TPN maintains intestinal structure and lactose digestive and hexose absorptive capacities, reduces intestinal hexose metabolism, and may facilitate the transition to enteral feeding in TPN-fed infants.
Cottrell
J J
JJ
USDA-ARS, Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA.
Stoll
B
B
Buddington
R K
RK
Stephens
J E
JE
Cui
L
L
Chang
X
X
Burrin
D G
DG
D000465:Algorithms; D000818:Animals; D000831:Animals, Newborn; D002245:Carbon Dioxide / Q000378:metabolism; D004247:DNA / Q000096:biosynthesis / Q000235:genetics; D053767:Glucagon-Like Peptide 2; D004763:Glucagon-Like Peptides / Q000627:therapeutic use*; D005947:Glucose / Q000008:administration & dosage / Q000378:metabolism; D051273:Glucose Transporter Type 2 / Q000378:metabolism; D006601:Hexoses / Q000378:metabolism*; D007082:Ileum / Q000378:metabolism; D007262:Infusions, Intravenous; D007583:Jejunum / Q000378:metabolism; D007700:Kinetics; D043322:Lactase / Q000378:metabolism; D008286:Malabsorption Syndromes / Q000517:prevention & control*; D010101:Oxygen Consumption / Q000502:physiology; D010289:Parenteral Nutrition, Total / Q000009:adverse effects*; D051269:Sodium-Glucose Transporter 1 / Q000378:metabolism; D013552:Swine; D014018:Tissue Distribution
D053767:Glucagon-Like Peptide 2; D051273:Glucose Transporter Type 2; D006601:Hexoses; D051269:Sodium-Glucose Transporter 1; D002245:Carbon Dioxide; D004763:Glucagon-Like Peptides; D004247:DNA; D043322:Lactase; D005947:Glucose